SGT Stock Overview Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. More details
Rewards Risk Analysis No risks detected for SGT from our risk checks.
See All Risk Checks Capture your thoughts, links and company narrative
Add notePrice History & Performance
Summary of share price highs, lows and changes for Seagen Historical stock prices Current Share Price US$208.60 52 Week High US$212.00 52 Week Low US$116.78 Beta 0.32 1 Month Change 6.27% 3 Month Change 6.92% 1 Year Change 74.04% 3 Year Change 28.86% 5 Year Change 318.88% Change since IPO 6,694.79%
Recent News & Updates
Seagen Inc. Files Form 15 Dec 26 Seagen Inc.(NasdaqGS:SGEN) dropped from FTSE All-World Index (USD) Pfizer Inc. (NYSE:PFE) completed the acquisition of Seagen Inc. (NasdaqGS:SGEN) from Baker/Tisch Investments, L.P, a funds managed by Baker Brothers Investments and others. Dec 14
Seagen Inc. Announces Phase 2 Study Evaluating the Antibody-Drug Conjugate ADCETRIS (brentuximab Vedotin) in Combination with the PD-1 Inhibitor Nivolumab and Standard Chemotherapy Agents Doxorubicin and Dacarbazine Dec 11
Seagen Inc. Announces Data from the Phase 3 HER2CLIMB-02 Clinical Trial of TUKYSA Dec 06 Astellas Pharma Inc. and Seagen Inc. Announces FDA Grants Priority Review for Supplemental Biologics License Application of Padcev with Keytruda for First-Line Treatment of Advanced Bladder Cancer Dec 02
See more updates
Seagen Inc. Files Form 15 Dec 26 Seagen Inc.(NasdaqGS:SGEN) dropped from FTSE All-World Index (USD) Pfizer Inc. (NYSE:PFE) completed the acquisition of Seagen Inc. (NasdaqGS:SGEN) from Baker/Tisch Investments, L.P, a funds managed by Baker Brothers Investments and others. Dec 14
Seagen Inc. Announces Phase 2 Study Evaluating the Antibody-Drug Conjugate ADCETRIS (brentuximab Vedotin) in Combination with the PD-1 Inhibitor Nivolumab and Standard Chemotherapy Agents Doxorubicin and Dacarbazine Dec 11
Seagen Inc. Announces Data from the Phase 3 HER2CLIMB-02 Clinical Trial of TUKYSA Dec 06 Astellas Pharma Inc. and Seagen Inc. Announces FDA Grants Priority Review for Supplemental Biologics License Application of Padcev with Keytruda for First-Line Treatment of Advanced Bladder Cancer Dec 02
Seagen Inc. Announces FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer Dec 01
Seagen Highlights First Solid Tumor Data for an ADCETRIS® (brentuximab vedotin) Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunotherapy of Cancer (SITC) Annual Meeting Nov 04
Third quarter 2023 earnings released: US$1.15 loss per share (vs US$1.03 loss in 3Q 2022) Nov 02 Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial
Seagen Inc. Announces to Highlight Overall Survival Data for Padcev and Tivdak During Presidential Symposium At Esmo Congress 2023 Oct 17
Seagen Inc. to Report Q3, 2023 Results on Nov 01, 2023 Oct 13
Astellas Pharma Inc. and Seagen Inc. Announces Positive Topline Results from the Phase 3 Ev-302 Clinical Trial Sep 23 Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy Sep 05
Seagen Inc. Announces Phase 3 HER2CLIMB-02 Clinical Trial of TUKYSA®? (tucatinib) in Combination with Antibody-Drug Conjugate Ado-Trastuzumab Emtansine Aug 17
Second quarter 2023 earnings released: US$1.13 loss per share (vs US$0.73 loss in 2Q 2022) Aug 03
Seagen Inc. to Report Q2, 2023 Results on Aug 02, 2023 Jul 13
Seagen Inc. Announces Phase 3 Trial of Adcetris (Brentuximab Vedotin) with Modified Chemo Regimen Shows Non-Inferiority with Unprecedented 3-Year Progression Free Survival of 94.9% Vs Less Tolerable International Standard of Care in Advanced Classical Hodgkin Lymphoma Jun 21
Seagen Announces ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 98% Overall Response Rate and 93% Complete Response Rate in Patients with Early-Stage Classical Hodgkin Lymphoma (cHL) Jun 13
First quarter 2023 earnings released: US$0.94 loss per share (vs US$0.74 loss in 1Q 2022) Apr 28
Now 20% undervalued Mar 11
Now 21% undervalued Feb 22
Full year 2022 earnings released: US$3.31 loss per share (vs US$3.71 loss in FY 2021) Feb 17 Seagen Inc. to Report Q4, 2022 Results on Feb 15, 2023 Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer Dec 21
Seagen Inc. Announces Results from Phase 2 Clinical Trial of ADCETRIS® (brentuximab vedotin) with Novel Immunotherapy Combination in Patients with Advanced- and Early-Stage Classical Hodgkin Lymphoma Dec 13
Independent Director recently sold €937k worth of stock Nov 17 Seagen Inc. Announces U.S. FDA Approval of New Indication for Adcetris® (Brentuximab Vedotin) for Children with Previously Untreated High Risk Hodgkin Lymphoma
Third quarter 2022 earnings released: US$1.03 loss per share (vs US$1.61 loss in 3Q 2021) Oct 28
Seagen Inc. Revises Revenue Guidance for the Full Year of 2022 Oct 28
Seagen Inc. to Report Q3, 2022 Results on Oct 27, 2022 Oct 07
Seagen Inc. Announces TUKYSA® (tucatinib) in Combination with Trastuzumab Granted Priority Review by FDA for Previously Treated HER2-Positive Metastatic Colorectal Cancer Sep 20
Astellas, Seagen and Merck Announce Results of Clinical Trial Investigating PADCEV(R) (Enfortumab Vedotin-Ejfv) with KEYTRUDA((R) (Pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer Sep 13
Seagen to Highlight Research in Urothelial and Colorectal Cancers At 2022 European Society for Medical Oncology (Esmo) Congress Sep 08
Merck’s Reportedly Talks to Acquire Seagen Hit Snag, Threatening Mega Pharma Deal Aug 27
Arbitrator Rules in Favor of Daiichi Sankyo Company, Limited in Dispute with Seagen Inc Aug 13
Second quarter 2022 earnings released: US$0.73 loss per share (vs US$0.47 loss in 2Q 2021) Jul 30
Seagen Inc. Revises Earnings Guidance for the Year 2022 Jul 29
Seagen Inc. to Report Q2, 2022 Results on Jul 28, 2022 Jul 09
Merck Reportedly in Advanced Talks to Buy Seagen Jul 07
Seagen Inc. Announces Full Results from the Pivotal Phase 2 MOUNTAINEER Trial, Which Showed TUKYSA (Tucatinib) in Combination with Trastuzumab Jul 03
Merck Reportedly Pushes Forward with Potential Deal for Seagen Jun 25
Merck, Other Suitors Reportedly Interested in Acquiring Seagen Jun 18
Genmab A/S and Seagen Inc. Present Data from Tisotumab Vedotin (TIVDAK) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting Jun 07
Takeda Pharmaceutical Company Limited and Seagen Inc. to Highlight ADCETRIS® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma May 27
Seagen Inc. Announces Positive Topline Results of Pivotal Phase 2 Clinical Trial of TUKYSA(R) (tucatinib) in Combination with Trastuzumab in HER2-Positive Metastatic Colorectal Cancer May 24
Seagen Announces Resignation of Clay Siegall as CEO May 18
Seagen Inc., Annual General Meeting, May 13, 2022 May 14 Seagen President, CEO and Chairman Clay Siegall Takes Leave of Absence
First quarter 2022 earnings released: US$0.74 loss per share (vs US$0.67 loss in 1Q 2021) May 01
Insufficient new directors Apr 27
Astellas Pharma Inc. and Seagen Inc. Announces European Commission Approves PADCEV™ (Enfortumab Vedotin) for Locally Advanced or Metastatic Urothelial Cancer Apr 14
Seagen to Highlight Preclinical Data for Enfortumab Vedotin and Two Novel Antibody-Drug Conjugates at AACR Annual Meeting Apr 09
Seagen Inc. to Report Q1, 2022 Results on Apr 28, 2022 Apr 08
Astellas Pharma Inc. and Seagen Inc. Announce CHMP Confirms Positive Opinion for PADCEV™ (Enfortumab Vedotin) in Locally Advanced or Metastatic Urothelial Cancer Mar 01
Genmab and Seagen Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma Feb 25
Seagen and Astellas Announce Initial Results of PADCEV (enfortumab vedotin-ejfv) in Patients With Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin Chemotherapy Feb 15
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 10
Seagen Inc. Provides Earnings Guidance for the Year 2022 Feb 10
ADCETRIS® Combination Significantly Improves Overall Survival in Newly Diagnosed Patients with Advanced Hodgkin Lymphoma Feb 04
Seagen Inc. Announces Executive Changes Feb 02
Seagen Canada Announces Availability of PADCEV® to Treat Advanced Bladder Cancer Jan 26
Seagen Inc. Announces Data from Phase I Clinical Trial Combining SEA-CD40 Jan 19
Astellas and Seagen Receive Positive CHMP Opinion for PADCEV™ (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer Dec 18
Seagen Announces Preliminary Results from Phase 2 Clinical Trial of ADCETRIS® (brentuximab vedotin) Dec 13
Seagen Announces Updated Results from Pivotal HER2CLIMB Trial Evaluating TUKYSA® (tucatinib) Dec 09
Seagen Inc. Announces Last Patient Enrolled in Phase 2 MOUNTAINEER Trial Evaluating TUKYSA® (Tucatinib) Regimen in HER2-Positive Metastatic Colorectal Cancer Oct 01
Japan’s MHLW Approves Astellas Pharma Inc. and Seagen Inc.'s PADCEV (enfortumab vedotin) for Advanced Urothelial Cancer Sep 29
U.S. Food and Drug Administration Grants Approval to TIVDAK Sep 24 Shareholder Returns SGT DE Biotechs DE Market 7D 3.4% -2.9% -2.6% 1Y 74.0% -14.7% 6.9%
See full shareholder returns
Return vs Market: SGT exceeded the German Market which returned 4.8% over the past year.
Price Volatility Is SGT's price volatile compared to industry and market? SGT volatility SGT Average Weekly Movement 2.0% Biotechs Industry Average Movement 6.8% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.2% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: SGT has not had significant price volatility in the past 3 months.
Volatility Over Time: SGT's weekly volatility (2%) has been stable over the past year.
About the Company Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases.
Show more Seagen Inc. Fundamentals Summary How do Seagen's earnings and revenue compare to its market cap? SGT fundamental statistics Market cap €39.61b Earnings (TTM ) -€688.56m Revenue (TTM ) €2.11b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) SGT income statement (TTM ) Revenue US$2.30b Cost of Revenue US$2.13b Gross Profit US$171.59m Other Expenses US$921.81m Earnings -US$750.22m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2023/12/14 00:08 End of Day Share Price 2023/12/13 00:00 Earnings 2023/09/30 Annual Earnings 2022/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Seagen Inc. is covered by 34 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Ishan Majumdar Baptista Research Emily Bodnar Berenberg George Farmer BMO Capital Markets Equity Research
Show 31 more analysts